SII Covovax inclusion in vaccination drive for 12-17 age group recommended by NTAGI panel
Advertisement
New Delhi: The Standing Technical Sub-Committee of the NTAGI has recommended inclusion of the Serum Institute's Covid jab Covovax in the national anti-coronavirus vaccination programme for children aged 12 to 17 years, sources said on Friday.
The National Technical Advisory Group on Immunisation (NTAGI) panel, at its meeting on Friday, also discussed reducing the gap between the second and precaution doses of vaccine from nine to six months and administering the additional dose early (before nine months) to those travelling abroad for education, employment, sporting events and business meetings.
Read also: Serum institute Covovax first Indian COVID vaccine to be sold in Europe: Adar Poonawalla
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.